Citations

Showing 10 of 108094 citations.

Has the Path to Practice Success Changed?
Bernard, Robert W.

Mayo Clinic

Aesthetic Surgery Journal | July 27, 2022 | Volume: 43 | Issue: 1 | Pages: 112-113

10.1093/asj/sjac201 | PMID 35894133 Get It

Utility of Carpal Tunnel Release and Ulnar Decompression in CMT1A and HNPP
Chompoopong, Pitcha , Niu, Zhiyv , Shouman, Kamal , Madigan, Nicolas N. , Sandroni, Paola , Berini, Sarah E. , Brault, Jeffrey S. , Boon, Andrea J. , Laughlin, Ruple S. , Thorland, Erik C., Mandrekar, Jay , Thorland, Erik, Klein, Christopher J , Chompoopong, Pitcha , Niu, Zhiyv , Shouman, Kamal , Shin, Alexander Y. , Klein, Christopher J.

Mayo Clinic

Muscle & Nerve | July 27, 2022 | Volume: 66 | Issue: 4 | Pages: 479-486

10.1002/mus.27687 | PMID 35894586 Get It

Abstract Introduction/Aims Carpal and cubital tunnel syndrome (CTS, CuTS) are common among patients with hereditary neuropathy with liability to pressure‐palsies (HNPP) and Charcot–Marie‐Tooth type 1A (CMT1A) and may impact quality of life. We aimed to evaluate the utility of nerve decompression surgeries in these patients. Methods Medical records were reviewed for patients with PMP22 mutations confirmed in Mayo Clinic laboratories from January 1999 to December 2020, who had CTS and CuTS and underwent surgical decompression. Results CTS occurred in 53.3% of HNPP and 11.5% of CMT1A, while CuTS was present in 43.3% of HNPP and 5.8% of CMT1A patients. CTS decompression occurred in 10‐HNPP and 5‐CMT1A patients, and CuTS decompression with/without transposition was performed in 5‐HNPP and 1‐CMT1A patients. In HNPP, electrodiagnostic studies identified median neuropathy at the wrist in 9/10 patients and ultrasound showed focal enlargements at the carpal and cubital tunnels. In CMT1A, median and ulnar sensory responses were all absent, and the nerves were diffusely enlarged. After CTS surgery, pain, sensory loss, and strength improved in 4/5 CMT1A, and 6/10 HNPP patients. Of clinical, electrophysiologic and ultrasound findings, only activity‐provoked features significantly correlated with CTS surgical benefit in HNPP patients (odds ratio = 117.0:95% confidence interval, 1.94 > 999.99, p = 0.01). One CMT1A and one HNPP patient improved with CuTS surgery while 2 HNPP patients worsened. Discussion CTS symptom improvement post‐surgery can be seen in CMT1A and (less frequent) in HNPP patients. CuTS surgery commonly worsened course in HNPP. Activity‐provoked symptoms in HNPP best informed benefits from CTS surgery.
Editorial Comment
Sharma, Vidit

Mayo Clinic

Journal of Urology | July 27, 2022 | Volume: 208 | Issue: 3 | Pages: 597-598

10.1097/ju.0000000000002740.02 | PMID 35892274 Get It

CCNB2 expression correlates with worse outcomes in breast cancer patients: a pooled analysis
Sun, Chenyu , Lowe, Scott , Bentley, Rachel , Zhou, Zhen , Cheng, Ce , Zhou, Qin , Zhou, Zhen , Sun, Chenyu , Ma, Shaodi

Mayo Clinic

Women & Health | July 27, 2022 | Volume: 62 | Issue: 7 | Pages: 655-663

10.1080/03630242.2022.2106530 | PMID 35892137 Get It

Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial
Maselli, Daniel B. , Atieh, Jessica , Clark, Matthew M. , Eckert, Deborah J., Taylor, Ann, Carlson, Paula, Burton, Duane D. , Busciglio, Irene, Harmsen, William S. , Camilleri, Michael , Maselli, Daniel, Eckert, Deborah, Acosta, Andres , Camilleri, M , Vella, Adrian , Acosta, Andrés

Mayo Clinic

Obesity | July 27, 2022 | Volume: 30 | Issue: 8 | Pages: 1608-1620

10.1002/oby.23481 | PMID 35894080 Get It

Abstract Objective This study aimed to determine the effects of a long‐acting glucagon‐like peptide‐1 (GLP‐1) receptor agonist, liraglutide, and placebo subcutaneously over 16 weeks on weight and gastric functions and to evaluate associations of single‐nucleotide polymorphisms in GLP1R (rs6923761) and TCF7L2 (rs7903146) with effects of liraglutide. Methods The study conducted a randomized, parallel‐group, placebo‐controlled, 16‐week trial of liraglutide, escalated to 3 mg subcutaneously daily in 136 otherwise healthy adults with obesity. Weight, gastric emptying of solids (GES), gastric volumes, satiation, and body composition measured at baseline and after treatment were compared in two treatment groups using analysis of covariance. Results Liraglutide ( n = 59) and placebo ( n = 65) groups completed treatment. Relative to placebo, liraglutide increased weight loss at 5 and 16 weeks (both p < 0.05), slowed time to half GES (T 1/2 ) at 5 and 16 weeks (both p < 0.001), and increased fasting gastric volume ( p = 0.01) and satiation ( p < 0.01) at 16 weeks. GES T 1/2 was positively correlated with weight loss on liraglutide (both p < 0.001). After 16 weeks of liraglutide, GLP1R rs6923761 (AG/AA vs. GG) was associated with reduced percent body fat ( p = 0.062), and TCF7L2 rs7903146 (CC vs. CT/TT) was associated with lower body weight ( p = 0.015). Conclusions Liraglutide, 3 mg, induces weight loss with delay in GES T 1/2 and reduces calorie intake. Slowing GES and variations in GLP1R and TCF7L2 are associated with liraglutide effects in obesity.
NFAT1 Orchestrates Spinal Microglial Transcription and Promotes Microglial Proliferation via c‐MYC Contributing to Nerve Injury‐Induced Neuropathic Pain
Jiang, Bao‐Chun , Ding, Tingyu, Guo, Chang‐Yun , Bai, Xue‐Hui , Cao, De‐Li, Sha, Wei‐Lin, Wu, Long‐Jun , Gao, Yong-Jing , Wu, Long-Jun , Wu, Xiao-Bo , Jiang, Ming

Mayo Clinic

Advanced Science | July 27, 2022 | Volume: 9 | Issue: 27 | Pages: No page available

10.1002/advs.202201300 | PMID 35892263 Get It

AbstractPeripheral nerve injury‐induced spinal microglial proliferation plays a pivotal role in neuropathic pain. So far, key intracellular druggable molecules involved in this process are not identified. The nuclear factor of activated T‐cells (NFAT1) is a master regulator of immune cell proliferation. Whether and how NFAT1 modulates spinal microglial proliferation during neuropathic pain remain unknown. Here it is reported that NFAT1 is persistently upregulated in microglia after spinal nerve ligation (SNL), which is regulated by TET2‐mediated DNA demethylation. Global or microglia‐specific deletion of Nfat1 attenuates SNL‐induced pain and decreases excitatory synaptic transmission of lamina II neurons. Furthermore, deletion of Nfat1 decreases microglial proliferation and the expression of multiple microglia‐related genes, such as cytokines, transmembrane signaling receptors, and transcription factors. Particularly, SNL increases the binding of NFAT1 with the promoter of Itgam, Tnf, Il‐1b, and c‐Myc in the spinal cord. Microglia‐specific overexpression of c‐MYC induces pain hypersensitivity and microglial proliferation. Finally, inhibiting NFAT1 and c‐MYC by intrathecal injection of inhibitor or siRNA alleviates SNL‐induced neuropathic pain. Collectively, NFAT1 is a hub transcription factor that regulates microglial proliferation via c‐MYC and guides the expression of the activated microglia genome. Thus, NFAT1 may be an effective target for treating neuropathic pain.
Comparative Efficacy Randomized Controlled Trials in Rheumatology Guidelines
Henry, Katie , Nepal, Desh , Valley, Erin, Pedersen, Connor , Duarte‐García, Alí , Putman, Michael , Duarte-García, Alí , Pedersen, Connor

Mayo Clinic

ACR Open Rheumatology | July 27, 2022 | Volume: 4 | Issue: 10 | Pages: 897-902

10.1002/acr2.11484 | PMID 35892138 Get It

BackgroundComparative efficacy randomized controlled trials (RCTs) compare two active interventions in a head‐to‐head design. They are useful for informing clinical practice guidelines, but the degree to which such trials inform clinical practice guidelines in rheumatology is unknown.MethodsThe American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) websites were searched from January 1, 2017, to June 12, 2021, for clinical practice guidelines. RCTs referenced by each guideline were identified, and information regarding design and outcomes were extracted. Clinical practice recommendations from each guideline were also analyzed.ResultsFifteen ACR‐ and nine EULAR‐endorsed guidelines were included, which cited 609 RCTs and provided 481 recommendations. Referenced RCTs enrolled an average of 418 patients (SD 985), most commonly evaluated biologic/targeted synthetic disease‐modifying antirheumatic drugs (70.1%), and infrequently used a head‐to‐head design (28%). A minority of recommendations received a high level of evidence (LOE) by the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) methodology (2.9%) or an “A” grade by the Oxford Centre for Evidence based Medicine Standards (OCEBM) methodology (28.9%). LOE was higher for recommendations informed by RCTs (P < 0.001) or head‐to‐head RCTs (P = 0.008). Many recommendations received a strong recommendation despite low (8 [2.6%]) or very low (25 [8.3%]) LOE.ConclusionLess than one in six rheumatology guideline recommendations are informed by head‐to‐head RCTs. Recommendations that were informed by head‐to‐head RCTs were more likely to have a high LOE by both GRADE and OCEBM. Efforts to introduce more comparative efficacy RCTs should be undertaken.
Genetic and immunohistochemical profiling of NK/T-cell lymphomas reveals prognostically relevant BCOR-MYC association
Oishi, Naoki , Satou, Akira , Miyaoka, Masashi , Kawashima, Ichiro , Segawa, Takahiro , Miyake, Kunio , Mochizuki, Kunio , Kirito, Keita , Feldman, Andrew L. , Nakamura, Naoya , Kondo, Tetsuo , Feldman, Andrew L , Oishi, Naoki

Mayo Clinic

Blood Advances | July 27, 2022 | Volume: 7 | Issue: 1 | Pages: 178-189

10.1182/bloodadvances.2022007541 | PMID 35882439 Get It

Abstract Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is an Epstein-Barr virus-positive, aggressive lymphoma with a heterogeneous cell of origin and variable clinical course. Several clinical prognostic indices have been proposed for ENKTL; however, there are few pathological biomarkers. This multi-institutional study sought to identify histologically assessable prognostic factors. We investigated mutation profiles by targeted next-generation sequencing (NGS) and immunohistochemical assessments of expression of MYC, Tyr705-phosphorylated (p-)STAT3, and CD30 in 71 ENKTL samples. The median age of the patients was 66 years (range, 6-100). The most frequent mutations were in STAT3 (27%), JAK3 (4%), KMT2D (19%), TP53 (13%), BCOR (10%), and DDX3X (7%). Immunohistochemistry (IHC) revealed that ENKTLs with STAT3 mutations exhibited higher expression of pSTAT3 and CD30. BCOR mutations were associated with increased MYC expression. Univariate analysis in the entire cohort showed that stage (II, III, or IV), BCOR mutations, TP53 mutations, and high MYC expression (defined as ≥40% positive neoplastic cells) were associated with reduced overall survival (OS). Multivariate modeling identified stage (II, III, or IV) and high MYC expression as independent adverse prognostic factors. In a subgroup analysis of patients treated with anthracycline (AC)-free chemotherapy and/or radiotherapy (RT) with curative intent, BCOR but not high MYC expression was an independent adverse prognostic factor. In conclusion, activating STAT3 mutations are common in ENKTLs and are associated with increased CD30 expression. MYC overexpression is, at least in part, associated with deleterious BCOR mutations, and this BCOR–MYC linkage may have prognostic significance, underscoring the potential utility of IHC for MYC in risk stratification of patients with ENKTL.
Transfusion-Transmitted Cache Valley Virus Infection in a Kidney Transplant Recipient With Meningoencephalitis
Al-Heeti, Omar, Wu, En‐Ling , Saluja, Rasleen K, Ramsey, Glenn , Matkovic, Eduard , Banach, Bridget S. , Wilson, Michael R. , Miller, Steve , McCabe, Muniba, Bari, Chowdhury, Zimler, Rebecca , Freeman, Debbie, Popovitch, Jonathan M., Annambhotla, Pallavi , Lehman, Jennifer , Fitzpatrick, Kelly A., Velez, Jason O. , Davis, Emily H. , Hughes, Holly R. , Panella, Amanda J., Staples, J. Erin , Gould, Carolyn V. , Wilson, Michael R , Ison, Michael G. , Saluja, Rasleen K, Ha, Kevin, Hall, Scott, Chiu, Charles Y. , Babiker, Hani M. , Freeman, Debbie, Popovitch, Jonathan, Brault, Aaron C. , van Duin, David

Mayo Clinic

Clinical Infectious Diseases | July 27, 2022 | Volume: 76 | Issue: 3 | Pages: e1320-e1327

10.1093/cid/ciac566 | PMID 35883256 Get It

Abstract Background Cache Valley virus (CVV) is a mosquito-borne virus that is a rare cause of disease in humans. In the fall of 2020, a patient developed encephalitis 6 weeks following kidney transplantation and receipt of multiple blood transfusions. Methods After ruling out more common etiologies, metagenomic next-generation sequencing (mNGS) of cerebrospinal fluid (CSF) was performed. We reviewed the medical histories of the index kidney recipient, organ donor, and recipients of other organs from the same donor and conducted a blood traceback investigation to evaluate blood transfusion as a possible source of infection in the kidney recipient. We tested patient specimens using reverse-transcription polymerase chain reaction (RT-PCR), the plaque reduction neutralization test, cell culture, and whole-genome sequencing. Results CVV was detected in CSF from the index patient by mNGS, and this result was confirmed by RT-PCR, viral culture, and additional whole-genome sequencing. The organ donor and other organ recipients had no evidence of infection with CVV by molecular or serologic testing. Neutralizing antibodies against CVV were detected in serum from a donor of red blood cells received by the index patient immediately prior to transplant. CVV neutralizing antibodies were also detected in serum from a patient who received the co-component plasma from the same blood donation. Conclusions Our investigation demonstrates probable CVV transmission through blood transfusion. Clinicians should consider arboviral infections in unexplained meningoencephalitis after blood transfusion or organ transplantation. The use of mNGS might facilitate detection of rare, unexpected infections, particularly in immunocompromised patients.
Presentation, Management, and Outcomes of Urinary Bladder Paraganglioma: Results From a Multicenter Study
Yu, Kai , Ebbehøj, Andreas , Obeid, Hiba, Vaidya, Anand , Else, Tobias , Wachtel, Heather , Main, Ailsa Maria , Søndergaard, Esben , Christensen, Louise Lehmann , Cohen, Debbie L. , Bennett, Bonita, Andersen, Marianne , Larsson, Catharina , Almeida, Madson Q. , Boorjian, Stephen A. , Ebbehøj, Andreas Ladefoged , Fishbein, Lauren , Bancos, Irina , Almeida, Madson Q , Juhlin, C. Christofer , Calissendorff, Jan , Young, William F. , Bancos, Irina

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 26, 2022 | Volume: 107 | Issue: 10 | Pages: 2811-2821

10.1210/clinem/dgac427 | PMID 35882219 Get It

Abstract Context Urinary bladder paraganglioma (UBPGL) is rare. Objective We aimed to characterize the presentation and outcomes of patients diagnosed with UBPGL. Methods We conducted a multicenter study of consecutive patients with pathologically confirmed UBPGL evaluated between 1971 and 2021. Outcomes included repeat bladder surgery, metastases, and disease-specific mortality. Results Patients (n=110 total; n=56 [51%] women) were diagnosed with UBPGL at a median age of 50 years (interquartile range [IQR], 36-61 years). Median tumor size was 2 cm (IQR, 1-4 cm). UBPGL was diagnosed prior to biopsy in only 37 (34%), and only 69 (63%) patients had evaluation for catecholamine excess. In addition to the initial bladder surgery, 26 (25%) required multiple therapies, including repeat surgery in 10 (9%). Synchronous metastases were present in 9 (8%) patients, and 24 (22%) other patients with UBPGL developed metachronous metastases at a median of 4 years (IQR, 2-10 years) after the initial diagnosis. Development of metachronous metastases was associated with younger age (hazard ratio [HR] 0.97; 95% CI, 0.94-0.99), UBPGL size (HR 1.69; 95% CI, 1.31-2.17), and a higher degree of catecholamine excess (HR 5.48; 95% CI, 1.40-21.39). Disease-specific mortality was higher in patients with synchronous metastases (HR 20.80; 95% CI, 1.30-332.91). Choice of initial surgery, genetic association, sex, or presence of muscular involvement on pathology were not associated with development of metastases or mortality. Conclusions Only a minority of patients were diagnosed before biopsy/surgery, reflecting need for better diagnostic strategies. All patients with UBPGL should have lifelong monitoring for development of recurrence and metastases.